These mechanisms help reduce the frequency and severity of IgE-mediated reactions, making omalizumab an effective treatment for conditions such as severe allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP) [48,49,50,51,52,53,54]. This evidence concerns the gene IGHE and allergic asthma.